CN119173539A - 多特异性构建体及其用途 - Google Patents

多特异性构建体及其用途 Download PDF

Info

Publication number
CN119173539A
CN119173539A CN202380024591.3A CN202380024591A CN119173539A CN 119173539 A CN119173539 A CN 119173539A CN 202380024591 A CN202380024591 A CN 202380024591A CN 119173539 A CN119173539 A CN 119173539A
Authority
CN
China
Prior art keywords
seq
amino acid
antibody
sdab
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380024591.3A
Other languages
English (en)
Chinese (zh)
Inventor
蒋雯卿
李键
陈曦
刘岩
郭炳诗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjing Biotechnology Hangzhou Co ltd
Original Assignee
I Mab Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Co Ltd filed Critical I Mab Biopharma Co Ltd
Publication of CN119173539A publication Critical patent/CN119173539A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202380024591.3A 2022-01-09 2023-01-09 多特异性构建体及其用途 Pending CN119173539A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/070870 2022-01-09
CN2022070870 2022-01-09
CN2022117334 2022-09-06
CNPCT/CN2022/117334 2022-09-06
PCT/CN2023/071334 WO2023131329A1 (en) 2022-01-09 2023-01-09 Multispecific constructs and uses thereof

Publications (1)

Publication Number Publication Date
CN119173539A true CN119173539A (zh) 2024-12-20

Family

ID=87073282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380024591.3A Pending CN119173539A (zh) 2022-01-09 2023-01-09 多特异性构建体及其用途

Country Status (9)

Country Link
US (1) US20250074995A1 (enExample)
EP (1) EP4460527A4 (enExample)
JP (1) JP2025501372A (enExample)
KR (1) KR20240133746A (enExample)
CN (1) CN119173539A (enExample)
AU (1) AU2023205989A1 (enExample)
CA (1) CA3248088A1 (enExample)
MX (1) MX2024008500A (enExample)
WO (1) WO2023131329A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US11739136B2 (en) * 2019-03-18 2023-08-29 Innovative Cellular Therapeutics Holdings, Ltd. Inducible dominant negative PD-1 and uses in adoptive cell therapy
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
PH12022552323A1 (en) * 2020-03-31 2023-12-04 Chugai Pharmaceutical Co Ltd Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
EP4138864A4 (en) * 2020-04-23 2024-07-10 Innovative Cellular Therapeutics Holdings, Ltd. Polyspecific binding molecules and their use in cell therapy
WO2021247474A1 (en) * 2020-06-02 2021-12-09 H. Lee Moffitt Cancer Center And Research Institute Inc. Sstr-binding chimeric antigen receptors
CN117355540A (zh) * 2021-05-21 2024-01-05 百济神州有限公司 抗cd137抗体和使用方法
CA3230426A1 (en) * 2021-09-03 2023-03-09 Novarock Biotherapeutics, Ltd. Bispecific binding proteins that bind cd137 and a tumor associated antigen

Also Published As

Publication number Publication date
WO2023131329A1 (en) 2023-07-13
EP4460527A4 (en) 2026-03-11
JP2025501372A (ja) 2025-01-17
CA3248088A1 (en) 2023-07-13
EP4460527A1 (en) 2024-11-13
MX2024008500A (es) 2024-08-26
KR20240133746A (ko) 2024-09-04
US20250074995A1 (en) 2025-03-06
AU2023205989A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
AU2022204817B2 (en) Fully Humanized Anti-B Cell Maturation Antigen (BCMA) Single-Chain Antibody and Use Thereof
CN113645996B (zh) 抗claudin 18抗体及其使用方法
AU2018396964C1 (en) Antibodies and variants thereof against PD-L1
US20170369586A1 (en) Humanized Anti-CD134 (OX40) Antibodies and Uses Thereof
AU2018366650A1 (en) Single-domain antibodies and variants thereof against PD-L1
EP4491635A2 (en) Anti-ccr8 antibodies
JP2018533360A (ja) ヒトｃｄ４０に特異的に結合するアゴニスト抗体及び使用方法
KR20140113912A (ko) Her3에 특이적인 결합 분자 및 이의 용도
KR20250134230A (ko) 다중특이적 항체 및 이의 용도
CN114008080B (zh) 抗pd-l1/抗lag-3多抗原结合蛋白及其使用方法
CN119998323A (zh) 使用抗c-c基序趋化因子受体8(ccr8)抗体治疗癌症的方法
KR20220148209A (ko) 항cd137 작제물 및 그 용도
EP3178848A1 (en) Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
WO2023131329A1 (en) Multispecific constructs and uses thereof
JP2024509191A (ja) 抗ｖｉｓｔａ構築物およびその使用
WO2021164701A1 (en) Fusion proteins and uses thereof
WO2024051752A9 (en) Multispecific constructs and uses thereof
WO2026092728A1 (en) Anti-igf-1r antibody constructs and uses thereof
CN120077071A (zh) 抗vista构建体及其用途
HK40108627A (zh) 抗vista的构建体及其用途
CN120322455A (zh) 特异性识别b和t淋巴细胞衰减器(btla)的抗体及其应用
CN118488965A (zh) 抗ox40抗体、多特异性抗体及其使用方法
CN117715934A (zh) 抗cd3构建体及其用途
HK40064186A (en) Anti-claudin 18 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250121

Address after: 310018 floor 6, building 3, Hexiang science and technology center, Qiantang new area, Hangzhou, Zhejiang

Applicant after: Tianjing Biotechnology (Hangzhou) Co.,Ltd.

Country or region after: China

Address before: Room 802, 8th Floor, West Tower, Building 1, No. 88 Shangke Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, 201210

Applicant before: Tianjing Biotechnology (Shanghai) Co.,Ltd.

Country or region before: China

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: 310018 floor 6, building 3, Hexiang science and technology center, Qiantang new area, Hangzhou, Zhejiang

Applicant after: Tianjing Biopharma (Hangzhou) Co., Ltd.

Address before: 310018 floor 6, building 3, Hexiang science and technology center, Qiantang new area, Hangzhou, Zhejiang

Applicant before: Tianjing Biotechnology (Hangzhou) Co.,Ltd.

Country or region before: China